Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine ER in OAB patients in primary care
NCT00645281Phase 4Completed
- Sponsor
- Viatris
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tolterodine in overactive bladder (OAB), sponsored by Viatris. Primary endpoint: Change from baseline to Week 12 in the micturition bladder diary variable related to the primary symptom of the patient at the time of study entry. Started Mar 2004; status: completed.
02
Drugs
tolterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00645281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645281.